Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STUART’s DIPRIVAN APPROVED FOR ADULT INTENSIVE CARE UNIT USE

Executive Summary

STUART's DIPRIVAN APPROVED FOR ADULT INTENSIVE CARE UNIT USE on March 8 for the sedation of intubated, mechanically ventilated or respirator-controlled patients. Diprivan (propofol), which has been marketed since 1989 as an anesthetic for inpatient and outpatient use, is the first agent to be labeled for sedation in critically ill patients in the U.S. The supplemental NDA was submitted in September 1991. Approval of the new indication for the general anesthetic came three-and-one-half months after a review by FDA's Anesthetic and Life Support Drugs Advisory Committee in open and closed sessions ("The Pink Sheet" Nov. 30, 1992, p. 9). The committee did not vote on the new indication in open session. "Diprivan provides medical professionals the ability to rapidly increase or decrease depth of sedation...within minutes," Stuart said in a March 10 press release. "Depending on their needs, patients can be placed in a deeper state of sedation to avoid stress and/or discomfort or can be wakened to allow [central nervous system] evaluation of interaction with medical professionals or family members." In clinical trials, Diprivan was compared to opioids and benzodiazepines in 550 ICU patients, of whom 302 received Diprivan. The anesthetic was found to be similar in efficacy to the other agents in maintenance of sedation. A higher incidence of hypotension in Diprivan-treated patients than in patients receiving comparator agents caused the company to reduce its initial dosing recommendation for Diprivan from 10 mcg/kg per minute to 5 mcg/kg per minute. Stuart filed data in May 1992 for use of Diprivan as a general anesthetic in the pediatric population. FDA has encouraged the company to submit an IND for study of the drug in the pediatric ICU setting despite reports that Diprivan may be associated with cardiac events in children being treated in the ICU. FDA's Anesthetic and Life Support Advisory Committee concluded in September that the link between Diprivan and pediatric deaths in the ICU could not be established from the existing data ("The Pink Sheet" Sept. 7, 1992, p. 14). Stuart said it continues to evaluate the need for clinical studies in this area.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel